Tumour-associated macrophages (TAMS): Disordered function, immune suppression and progressive tumour growth

Journal of the Royal College of Surgeons of Edinburgh

Volumn 45, Issue 1, 2000, Pages 1-16

  Al Sarireh, Bilal ^a   Eremin, O ^a  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

Anti tumour activity; Apoptosis; Chemotactic factors; Cytokins interleukin 1; Ecosanoids; Free radicles; Growth factors; Immunosuppression; Interleukin 10; Macriphage; Promotion of tumour growth; Transforming growth factor ; Tumour necrosis factor

Indexed keywords

CANCER GROWTH FACTOR; COLONY STIMULATING FACTOR; CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; ICOSANOID; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 2; MONOCYTE CHEMOTACTIC PROTEIN 3; PROSTANOID; PROTEIN P40; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR; VASCULOTROPIN;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL; CELL INFILTRATION; CELL INTERACTION; CELL LINEAGE; CELL TRANSPORT; CYTOKINE RELEASE; CYTOTOXICITY; GROWTH INHIBITION; HOST RESISTANCE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNOCOMPETENT CELL; INFLAMMATORY CELL; INHIBITION KINETICS; LEUKOCYTE FUNCTION; MONONUCLEAR CELL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REVIEW; SOLID TUMOR; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR IMMUNOLOGY;

APOPTOSIS; CHEMOTACTIC FACTORS, MACROPHAGE; CYTOKINES; DISEASE PROGRESSION; HUMANS; IMMUNOSUPPRESSION; MACROPHAGES; NEOPLASMS;

EID: 0034143110     PISSN: 00358835     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (205)

1. Van-Furth R. In Galin JI, Goldestein IM, Snyderman R, eds. Inflammation: Basic Principles and Clinical Correlates. New York: Ravens Press, 1988; 281
2. Thorens B, Mermod A Vassalli P. Phagocytosis and inflammatory stimuli induce GM-CSF mRNA in macrophages through posttranscriptional regulation. Cell 1987; 48: 671-9
3. Navarro S, Debili N, Bernaudin JF, Vainchenker W, Doly J. Regulation of the expression of IL-6 in human monocytes. J Immunol 1989; 142: 4339-45
4. Eierman DF, ohnson JCE, Haskill JS. Human monocyte inflammatory mediator gene expression is selectively regulated by adherence substrates. J Immunol 1989; 142: 1970-6
5. Auger MJ, Ross JA. The biology of macrophage. In Lewis CE, McGee JO, eds. The Macrophage. Oxford: Oxford University Press, 1992; 2-74
6. Mantovan, A, Bottazzi B, Colotta F, Sozzani S, Ruco L. The origin and function of tumor-associated macrophages. Immunol Today. 1992;13:265-70
7. Mantovani A. Tumor-associated macrophages in neoplastic progression: a paradigm for the in vivo function of chemokines. Biology of Disease 1. U.S.A, 1994, 5.
8. Mantovani A, Bottazi B, Sozzani S, Peri G, Allavena P, Dong QG, Vecchi A, colotta R Cytokine Regulation of Monocyte Recruitment. Arch Immunol Ther Exp (Warsz). 1995; 43:149-52
9. van-Ravenswaay-Claasen HH, Kluin PM, Fleuren GJ. Tumor infiltrating cells in human cancer. On the possible role of CD 16+ macrophages in antitumor cytotoxicity. Lab Invest 1992; 67: 166-74
10. O'Sullivan C, Lewis CE, Harris AL, McGee JO. Secretion of epidermal growth factor by macrophages associated with breast carcinoma. Lancet 1993; 342: 148-9. [Comment in: Lancet 1993; 342: 872-3
11. Toomey D, Harmey J, Condron C, Kay E, Bouchier-Hayes D. Phenotyping of immune cell infiltrates in breast and colorectal tumours. Immunol Invest 1999; 28: 29-41
12. Mantovani A, Ming WJ, Balotta C, Abdeljalil B, Bottazzi B. Origin and regulation of tumor-associated macrophages: the role of tumor-derived chemotactic factor. Biochim Biophys Acta 1986; 865:59-67
13. Volodko N, Reiner A, Rudas M, Jakesz R. Tumour-associated macrophages in breast cancer and their prognostic correlations. Breast 1998; 7: 99-105
14. Mills CD, Shearer J, Evans R, Caldwell MD. Macrophage arginine metabolism and the inhibition or stimulation of cancer. J Immunol 1992; 149: 2709-14
15. Elgert KD, Alleva DG, Mullins DW. Tumor-induced immune dysfunction: the macrophage connection. J Leukoc Biol 1998; 64:275-90
16. Grabbe S, Bruvers S, Beissert S, Granstein RD. Interferongamma inhibits tumor antigen presentation by epidermal antigen-presenting cells. J Leukoc Biol 1994; 55: 695-701
17. Blachere NE, Li Z, Chandawarkar RY, Suto R, Jaikaria NS, Basu S, Udono H, Srivastava PK. Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity. J Exp Med 1997; 186: 1315-22
18. Sunderkotter C, Steinbrink K, Goebeler M, Bhardwaj R, Sorg C. Macrophages and angiogenesis. J Leukoc Biol 1994; 55: 410-22
19. Parajuli P, Singh SM. Alteration in IL- 1 and arginase activity of tumor-associated macrophages: a role in the promotion of tumor growth. Cancer Lett 1996; 107: 249-56
20. Alleva DG, Burger CJ, Elgert KD. Tumor-induced regulation of suppressor macrophage nitric oxide and TNF-alpha production. Role of tumor-derived IL-10, TGF-beta, and prostaglandin E2. J Immunol 1994; 153: 1674-86.
21. Aoe T, Saito T. Towards immuno-modulation through the molecular mechanism of lymphocyte activation. Nippon Rinsho; 1995; 53: 2331-9
22. Aso H, Tamura K, Yoshie O, Nakamura T, Kikuchi S, Ishida N. Impaired NK response of cancer patients to IFN-alpha but not to IL-2: correlation with serum immunosuppressive acidic protein (IAP) and role of suppressor macrophage. Microbiology & Immunology 1992; 36: 1087-97
23. Evans R. Macrophages in syngeneic animal tumours. Transplantation 1972; 14: 468-73.
24. O'Sullivan C, Lewis CE. Tumour-associated leucocytes: friends or foes in breast carcinoma. Journal of Pathology 1994; 172: 229-35
25. Brunda MJ, Sulich V, Wright RB, Palleroni AV. Tumoricidal activity and cytokine secretion by tumor-infiltrating macrophages. Int J Cancer 1991; 48: 704-8.
26. Bucana CD, Fabra A, Sanchez R, Fidler IJ. Different patterns of macrophage infiltration into allogeneic-murine and xenogeneic-human neoplasms growing in nude mice. Am J Pathol 1992; 141: 1225-36
27. Walter S, Bottazzi B, Govoni D, Colotta F, Mantovani A. Macrophage infiltration and growth of sarcoma clones expressing different amounts of monocyte chemotactic protein/JE. Int J Cancer 199 1; 49: 431-5
28. Pupa SM, Bufalino R, Invernizzi AM, Andreola S, Rilke F, Lombardi L, Colnaghi MI, Menard S. Macrophage infiltrate and prognosis in c-erbB-2-overexpressing breast carcinomas [see comments]. Comment in: J Clin Oncol 1996 Aug;14(8):2406-7. Journal of Clinical Oncology 1996; 14: 85-94
29. Seljelid R. Tumour immunology: alternative perspectives. Scan J Immunol 1997; 46: 437-44.
30. Munthe-Kaas AC, Berg T, Seglen PO, Seljelid R. Mass isolation and culture of rat kupffer cells. J Exp Med 1975; 141:1-10.
31. Hakansson L, Adell G, Boeryd B, Sjogren F, Sjodahl R. Infiltration of mononuclear inflammatory cells into primary colorectal carcinomas: an immunohistological analysis. British Journal of Cancer 1997; 75: 374-80
32. Bottazzi B, Polentarutti N, Acero R, Balsari A, Boraschi D, Ghezzi P, Salmona M, Mantovani A. Regulation of the macrophage content of neoplasms by chemoattractants. Science 1983; 220: 210
33. Benomar A, Ming WJ, Taraboletti G, Ghezzi P, Balotta C, Cianciolo GJ, Snyderman R, Dore JF, Mantovani A. Chemotactic factor and P15E-related chemotaxis inhibitor in human melanoma cell lines with different macrophage content and tumorigenicity in nude mice. J Immunol 1987; 138: 2372-9
34. Cianciolo G, Hunter J, Silva J, Haskill JS, Snyderman R. Inhibitors of monocyte responses to chemotaxins are present in human cancerous effusions and react with monoclonal antibodies to the P15(E) structural protein of retroviruses. J Clin Invest 198 1; 68: 831-44
35. Furutani Y, Nomura H, Notake M, Oyamada Y, Fukui T, Yamada M, Larsen CG, Oppenheim JJ, Matsushima K. Cloning and sequencing of the cDNA for human monocyte chemotactic and activating factor (MCAF). Biochem Biophys Res Commun 1989; 159: 249-55
36. Zachariae CO, Anderson AO, Thompson HL, Appella E, Mantovani A, Oppenheim JJ, Matsushima K. Properties of monocyte chemotactic and activating factor (MCAF) purified from a human fibrosarcoma cell line. J Exp Med 1990; 171: 2177-82.
37. Bottazzi B, Walter S, Govoni D, Colotta F, Mantovani A. Monocyte chemotactic cytokine gene transfer modulates macrophage infiltration, growth, and susceptibility to IL-2 therapy of a murine melanoma. J Immunol 1992; 148: 1280-5
38. Valkovic T, Lucin K, Krstulja M, Dobi-Babic R, Jonjic N. Expression of monocyte chemotactic protein-1 in human invasive ductal, breast cancer. Pathology, Research & Practice 1998, 194, 335-40.
39. Opdenakker G, Van-Damme J. Cytokines and proteases in invasive processes: molecular similarities between inflammation and cancer. Cytokine 1992; 4: 251-8
40. Hildenbrand R, Wolf G, Bohme B, Bleyl U, Steinborn A. Urokinase plasminogen activator receptor (CD87) expression of tumor-associated macrophages in ductal carcinoma in situ, breast cancer, and resident macrophages of normal breast tissue. J Leukoc Biol 1999; 66: 40-9.
41. Jiang Y, Beller DI, Frendl G, Graves DT. Monocyte chemoattractant protein-1 regulates adhesion molecule expression and cytokine production in human monocytes. J Immunol 1992; 148: 2423-8
42. Rojas A, Delgado R, Glaria L, Palacios M. Monocyte chemotactic protein-1 inhibits the induction of nitric oxide synthase in J774 cells. Biochem Biophys Res Commun 1993; 196: 274-9
43. Graves DT, Jiang Y Chemokines, a family of chemotactic cytokines. [Review] [106 refs]. Critical Reviews in Oral Biology & Medicine 1995, 6, 109-18.
44. Fioretti F, Fradelizi D, Stoppacciaro A, Ramponi S, Ruco L, Minty A, Sozzani S, Garlanda C, Vecchi A, Mantovani A. Reduced tumorigenicity and augmented leukocyte infiltration after monocyte chemotactic protein-3 (MCP-3) gene transfer: perivascular accumulation of dendritic cells in peritumoral tissue and neutrophil recruitment within the tumor. J Immunol 1998; 161: 342-6.
45. Bottazzi B, Erba E, Nobili N, Fazioli F, Rambaldi A, Mantovani A. A paracrine circuit in the regulation of the proliferation of macrophages infiltrating murine sarcomas. J Immunol 1990; 144: 2409-12.
46. Fu YX, Cai JP, Chin YH, Watson GA, Lopez DM. Regulation of leukocyte binding to endothelial tissues by tumor-derived GM-CSF. Int J Cancer 1992; 50: 585-8
47. Dougherty ST, Eaves CJ, McBride WH, Dougherty GJ. Role of macrophage-colony-stimulating factor in regulating the accumulation and phenotype of tumor-associated macrophages. Cancer Immunology, Immunotherapy 1997, 44,165-72.
48. Dvorak HF, Nagy JA, Dvorak AM. Structure of solid tumors and their vasculature: implications for therapy with monoclonal antibodies. Cancer Cells 1991; 3: 77-85
49. Ha SJ, Lee CH, Lee SB, Kim CM, Jang KL, Shin HS, Sung YC. A novel function of IL-12p4O as a chemotactic molecule for macrophages. J Immunol 1999; 163: 2902-8.
50. Mahoney KH, Heppner GH. FACS analysis of tumor-associated macrophage replication: differences between metastatic and nonmetastatic murine mammary tumors. J Leukoc Biol 1987; 41: 205-11.
51. Scholl SM, Pallud C, Beuvon F, Hacene K, Stanley ER, Rohrschneider L, Tang R, Pouillart P, Lidereau R. Anti-colony-stimulating factor-I antibody staining in primary breast adenocarcinomas correlates with marked inflammatory cell infiltrates and prognosis. Journal of the National Cancer Institute 1994; 86: 120-6
52. Rilke F, Colnaghi MI, Cascinelli N, Andreola S, Baldini MT, Bufalino R, Della-Porta G, Menard S, Pierotti MA, Testori A. Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer 199 1; 49: 44-9
53. Leek RD, Lewis CE, Whitehouse R, Greenall M, Clarke J, Harris AL. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Research 1996; 56: 4625-9
54. Salvesen H, Akslen L. Significance of tumour-associated macrophages, vascular endothelial growth factor and thrombospondin-1 expression for tumour angiogenesis and prognosis in endometrial carcinomas. Int J Cancer 1999; 84: 539-43
55. Takanami I, Takeuchi K, Kodaira S. Tumor-associated macrophage infiltration in pulmonary adenocarcinoma: association with angiogenesis and poor prognosis. Oncology 1999; 57:138-42
56. Semeraro N, Montemurro P, Conese M, Giordano D, Stella M, Restaino A, Cagnazzo G, Colucci M. Procoagulant activity of mononuclear phagocytes from different anatomical sites in patients with gynecological malignancies. Int J Cancer 1990; 45: 251-4
57. van-Netten JP, Ashmead BJ, Parker RL, Thornton IG, Fletcher C, Cavers D, Coy P, Brigden ML. Macrophage-tumor cell associations: a factor in metastasis of breast cancer? J Leukoc Biol 1993; 54: 360-2
58. Mussoni L, Riganti M, Acero R, Erroi A, Conforti G, Mantovani A, Donati M. Macrophages associated with murine tumours express plasminogen activator activity. Int J Cancer 1988; 41: 227-30
59. Dinapoli MR, Calderon CL, Lopez DM.The altered tumoricidal capacity of macrophages isolated from tumor-bearing mice is related to reduce expression of the inducible nitric oxide synthase gene. Journal of Experimental Medicine 1996; 183: 1323-9
60. Young MR, Wright MA, Coogan M, Young ME, Bagash J. Tumor-derived cytokines induce bone marrow suppressor cells that mediate immunosuppression through transforming growth factor beta. Cancer Immunology, Immunotherapy 1992; 35: 14-18
61. Metzger Z, Hoffeld JT, Oppenheim JJ. Macrophage-mediated suppression. I. Evidence for participation of both hdyrogen peroxide and prostaglandins in suppression of murine lymphocyte proliferation. J Immunol 1980; 124: 983-8.
62. Akdis CA, Blaser K. IL- 10-induced anergy in peripheral T cell and reactivation by microenvironmental cytokines: two key steps in specific immunotherapy. FASEB Journal 1999; 13: 603-9
63. Key ME. Macrophages in cancer metastases and their relevance to metastatic growth. Cancer Metastasis Reviews 1983; 2: 75-88
64. Keever-Taylo, CA, Witt PL, Truitt RL, Ramanujam S, Borden EC, Ritch PS. Hematologic and immunologic evaluation of recombinant human interleukin-6 in patients with advanced malignant disease: evidence for monocyte activation. Journal of Immunotherapy with Emphasis on Tumor Immunology 1996; 19:231-43
65. Fidler IJ. Macrophages and metastasis-a biological approach to cancer therapy. Cancer Research 1985; 45: 4714-26
66. Andreesen R, Hennemann B, Krause SW. Adoptive immunotherapy of cancer using monocyte-derived macrophages: rationale, current status, and perspectives. [Review] [82 refs]. J Leukoc Biol 1998; 64: 419-26.
67. Fidler IJ. Eradication of cancer metastasis by tumoricidal macrophages. Advances in Experimental Medicine & Biology 1988; 233: 415-23
68. Owen MR, Sherratt JA. Modelling the macrophage invasion of tumours: effects on growth and composition. IMA Journal of Mathematics Applied in Medicine & Biology 1998; 15: 165-85
69. Killion JJ, Fidler IJ. Therapy of cancer metastasis by tumoricidal activation of tissue macrophages, using liposome-encapsulated immunomodulators. Pharmacology & Therapeutics 1998; 78: 141-54
70. Colombo MP, Modesti A, Parmiani G, Forni G. Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk. Cancer Research 1992; 52: 4853-7
71. Somers SD, Adams DO. Enhancement of selective tumor cell binding by activated murine macrophages in response to phorbol myristate acetate. J Immunol 1986; 136: 2323-32.
72. van-Hilten JA, Ben-Efraim S, Zijlstra FJ, I L Bonta. Leukotriene C4 is an essential 5-lipoxygenase intermediate in A23187-induced macrophage cytostatic activity against P815 tumor cells. Prostaglandins Leukot Essent Fatty Acids 1990; 39: 283-90
73. Elliott GR, Tak C, Pellens C, Ben-Efraim S, Bonta IL. Indomethacin stimulation of macrophage cytostasis against MOPC-315 tumor cells is inhibited by both prostaglandin E2 and nordihydroguaiaretic acid, a lipoxygenase inhibitor. Cancer Immunology, Immunotherapy 1988; 27: 133-6
74. Snider ME, Fertel RH, Zwilling BS. Prostaglandin regulation of macrophage function: effect of endogenous and exogenous prostaglandins. Cellular Immunology 1982; 74: 234-42
75. Taffet SM, Eurell TE, Russell SW. Regulation of macrophage-mediated tumor cell killing by prostaglandins: comparison of the effects of PGE2 and PGI2. Prostaglandins 1982; 24: 763-74
76. Drapier JC, Petit IF. Development of antitumor activity in LPS-stimulated mouse granuloma macrophages. Regulation by eicosanoids. Inflammation 1986; 10: 195-204
77. Ben-Efraim S, Tak C, Fieren MJ, Romijn JC, Beckmann I, Bonta IL. Activity of human peritoneal macrophages against a human tumor: role of tumor necrosis factor-alpha, PGE2 and nitrite, in vitro studies. Immunology Letters 1993; 37: 27-33
78. Kunkel SL, Spengler M, May MA, Spengler R, Larrick J, Remick D. Prostaglandin E2 regulates macrophage-derived tumor necrosis factor gene expression. Journal of Biological Chemistry 1988; 263: 5380-4
79. Schade UF, Ernst M, Reinke M, Wolter DT. Lipoxygenase inhibitors suppress formation of tumor necrosis factor in vitro and in vivo. Biochem Biophys Res Commun 1989; 159: 748-54
80. Fieren MW, van-den-Bemd GJ, Ben-Efraim S, Bonta IL. Prostaglandin E2 inhibits the release of tumor necrosis factor-alpha, rather than interleukin 1 beta, from human macrophages. Immunology Letters 1992; 31: 85-90
81. Granger GA, Weiser RS. Homograft target cells: contact destruction in vitro by immune macrophages. Science 1966; 151: 97-9
82. Holtermann OA, Klein E, Casale GP. Selective cytotoxicity of peritoneal leucocytes for neoplastic cells. Cellular Immunology 1973; 9:339-52
83. Bonta IL, Ben-Efraim S. Involvement of inflammatory mediators in macrophage antitumor activity. J Leukoc Biol 1993; 54: 613-26.
84. Adams DO, Hamilton TA. Macrophages as destructive cells in host defense. In Gallin JI, Goldestein IM, Snyderman R, eds. Inflammation-basic principles and clinical correlates. New York, Ravens Press, 1992, 637-622.
85. Bucana C, Hoyer LC, Hobbs B, Breesman S, McDaniel M, Hanna MGJ. Morphological evidence for the translocation of lysosomal organelles from cytotoxic macrophages into the cytoplasm of tumor target cells. Cancer Research 1976; 36: 4444-58
86. Marino PA, Adams DO. Interaction of Bacillus Calmette-Guerin-activated macrophages and neoplastic cells in vitro. I. Conditions of binding and its selectivity. Cellular Immunology 1980; 54:11-25
87. Marino PA, Adams DO. Interaction of Bacillus Calmette-Guerin-activated macrophages and neoplastic cells in vitro II. The relationship of selective binding to cytolysis. Cellular Immunology 1980; 54: 26-35
88. Marino PA, Whisnant CC, Adams DO. Binding of bacillus Calmette-Guerin-activated macrophages to tumor targets. Selective inhibition by membrane preparations from homologous and heterologous neoplastic cells. J Exp Med 1981; 154: 77-87
89. Somers SD, Whisnant CC, Adams DO. Quantification of the strength of cell-cell adhesion: the capture of tumor cells by activated murine macrophages proceeds through two distinct stages. J Immunol 1986; 136: 1490-6
90. Itoh K, Platsoucas CD, Balch CM. Monocyte- and natural killer cell-mediated spontaneous cytotoxicity against human noncultured solid tumor cells. Cellular Immunology 1987; 108:495-500
91. Kimura S, Sone S, Takahashi K, Uyama T, Ogura T, Monden Y. Antitumour potential of pleural cavity macrophages in lung cancer patients without malignant effusion. British Journal of Cancer 1989; 59: 535-9
92. De Young NJ, Gill PG. Monocyte antibody-dependent cellular cytotoxicity in cancer patients. Cancer Immunology, Immunotherapy 1984; 18:54-8
93. Santoro MG, Philpott GW, Jaffe BM. Inhibition of tumour growth in vivo and in vitro by prostaglandin E. Nature 1976; 263: 777-9
94. Ben-Efraim S, Tak C, Bonta IL. Macrophage cytokines render WEHI-3B tumor cells susceptible to cytostasis by prostaglandins. Prostaglandins Leukot Essent Fatty Acids 1990; 40: 163-7
95. Renz H, Gong JH, Schmidt A, Nain M, Gemsa D. Release of tumor necrosis factor-alpha from macrophages. Enhancement and suppression are dose-dependently regulated by prostaglandin E2 and cyclic nucleotides. J Immunol 1988; 141: 2388-93
96. Scales WE, Chensue SW, Otterness I, Kunkel SL. Regulation of monokine gene expression: prostaglandin E2 suppresses tumor necrosis factor but not interleukin-1 alpha or beta-mRNA and cell-associated bioactivity. J Leukoc Biol 1989; 45: 416-21
97. Rola-Pleszczynski M, Thivierge M, Gagnon N, Lacasse C, Stankova. J. Differential regulation of cytokine and cytokine receptor genes by PAF, LTB4 and PGE2. Journal of Lipid Mediators 1993; 6,175-81
98. Schade UF, Engel R, Jakobs D. The role of lipoxygenases in endotoxin-induced cytokine production. Progress in Clinical & Biological Research 1991; 367: 73-82
99. Tartour E, Fridman WH. Cytokines and cancer. International Reviews of Immunology 1998; 16: 683-704
100. Cerami A, Beutler B. The role of cachectin/TNF in endotoxic shock and cachexia. Immunol Today 1988; 9: 28-31
101. de-Waal-Malefyt R, Abrams J, Bennett B, Figdor CG, de-Vries JE. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991; 174:1209-20.
102. Philip R, Epstein LB. Tumour necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself, gamma-interferon and interleukin-1. Nature 1986; 323: 86-9
103. Borden EC, Ball LA. Interferons: biochemical, cell growth inhibitory, and immunological effects. Progress in Hematology 1981; 12: 299-339
104. Beutler, Cerami. Cachectin and tumour necrosis factor as two sides of the same biological coin. Nature 1986; 320: 584-8
105. Bonta IL, Ben-Efraim S, Mozes T, Fieren MW. Tumour necrosis factor in inflammation: relation to other mediators and to macrophage antitumour defence. Pharmacological Research 1991; 24: 115-30
106. Ben-Efraim S, onta BL. Modulation of antitumour activity of macrophages by regulation of eicosanoids and cytokine production. International Journal Of Immunopharmacology 1994; 16:397-9
107. Ichinose Y, Tsao JY, Fidler IJ. Destruction of tumor cells by monokines released from activated human blood monocytes: evidence for parallel and additive effects of IL-1 and TNF. Cancer Immunology, Immunotherapy 1988; 27: 7-12
108. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proceedings of the National Academy of Sciences of the United States of America 1975; 72:3666-70
109. Klostergaard J, Leroux SM, Ezell SM, Kull FCJ. Tumoricidal effector mechanisms of murine Bacillus Calmette-Guerin-activated macrophages: mediation of cytolysis, mitochondrial respiration inhibition, and release of intracellular iron by distinct mechanisms. Cancer Research 1987; 47: 2014-9
110. DeMarco R, Ensor JE, Hasday JD. Tumor-stimulated release of tumor necrosis factor-alpha by human monocyte-derived macrophages. Cellular Immunology 1992; 140:304-18
111. Urban JL, Shepard HM, Rothstein JL, Sugarman BJ, Schreiber H. Tumor necrosis factor: a potent effector molecule for tumor cell killing by activated macrophages. Proceedings of the National Academy of Sciences of the United States of America 1986; 83: 5233-7
112. Erickson SL, de-Sauvage FJ, Kikly K, Carver-Moore K, Pitts-Meek S, Gillett N, Sheehan KC, Schreiber RD, Goeddel DV, Moore MW. Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice. Nature 1994; 372: 560-3
113. Hibbs JB. The macrophage as a tumoricidal effector cell: a review of in vitro and in vivo studies on the mechanism of the activated macrophage nonspecific cytotoxicity reaction. New York, Academic Press, 1976.
114. Mytar B, Siedlar M, Woloszyn M, Ruggiero I, Pryjma J, Zembala M. Induction of reactive oxygen intermediates in human monocytes by tumour cells and their role in spontaneous monocyte cytotoxicity. British Journal of Cancer 1999; 79: 737-43
115. Lewis CE, McGee JO. The macrophage. Oxford, Oxford University Press, 1992.
116. Martin JH, Edwards SW. Changes in mechanisms of monocyte/macrophage-mediated cytotoxicity during culture. Reactive oxygen intermediates are involved in monocyte-mediated cytotoxicity, whereas reactive nitrogen intermediates are employed by macrophages in tumor cell killing. J Immunol 1993; 150: 3478-86
117. Morris SMJ, Billiar TR. New insights into the regulation of inducible nitric oxide synthesis. [Review] [102 refs]. American Journal of Physiology 1994, 266, E829-39.
118. Hibbs JBJ, Vavrin Z, Taintor RR. L-arginine is required for expression of the activated macrophage effector mechanism causing selective metabolic inhibition in target cells. J Immunol 1987; 138: 550-65.
119. Stuehr DJ, Nathan CF. Nitric oxide. A macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells. J Exp Med 1989; 169: 1543-55.
120. Hibbs JBJ, Taintor RR, Vavrin Z, Rachlin EM. Nitric oxide: a cytotoxic activated macrophage effector molecule [published erratum appears in Biochem Biophys Res Commun 1989 Jan 31;158(2):624]. Biochem Biophys Res Commun 1988; 157: 87-94
121. Albina JE, Mastrofrancesco B. Modulation of glucose metabolism in macrophages by products of nitric oxide synthase. American Journal of Physiology 1993; 264: C1594-9.
122. Lepoivre M, Flaman JM, Henry Y. Early loss of the tyrosyl radical in ribonucleotide reductase of adenocarcinoma cells producing nitric oxide. Journal of Biological Chemistry 1992; 267: 2294-3000
123. Albina JE, Reichner JS. Role of nitric oxide in mediation of macrophage cytotoxicity and apoptosis. Cancer & Metastasis Reviews 1998; 17: 39-53
124. Bonner FT, Stedman G. The chemistry of nitric oxide and redox-related species. In Feelish M, Stamler JS, eds. Methods in Nitric Oxide Research. Chichester, 1996
125. Stamler JS, Feelish M. Biochemistry of nitric oxide and redox-related species. In Feelish M, Stamler JS, eds. Methods in Nitric Oxide Research 19-27. Chichester, 1996
126. Nguyen T, Brunson D, Crespi CL, Penman BW, Wishnok JS, Tannenbaum SR. DNA damage and mutation in human cells exposed to nitric oxide in vitro. Proceedings of the National Academy of Sciences of the United States of America 1992; 89: 3030-4
127. Kroncke KD, Fehsel K, Schmidt T, Zenke FT, Dasting I, Wesener JR, Bettermann H, Breunig KD, Kolb-Bachofen V. Nitric oxide destroys zinc-sulfur clusters inducing zinc release from metallothionein and inhibition of the zinc finger-type yeast transcription activator LAC9. Biochem Biophys Res Commun 1994; 200: 1105-10
128. Albina JE, Mills CD, Caldwell MD. Alteration in macrophage physiology associated with the metabolism of L-arginine through the oxidative L-arginine deiminase pathway. In Moncada S, Higgs EA, eds. Nitric Oxide from L-arginine: A Bioregulatory System1990. Amesterdam, Elsevier Science Publishers B.V, 1990.
129. Albina JE, Cui S, Mateo RB, Reichner JS. Nitric oxide-mediated apoptosis in murine peritoneal macrophages. J Immunol 1993; 150: 5080-5
130. Chambers VC, Weiser RS. The ultrastructure of target cells and immune macrophages during their interaction in vitro. Cancer Research 1969; 29: 301-17
131. Chambers VC, Weiser RS. The ultrastructure of sarcoma I cells and immune macrophages during their interaction in the peritoneal cavities of immune C57BL-6 mice. Cancer Research 1972; 32: 413-9
132. Wyllie AH, Kerr JF, Currie AR. Cell death: the significance of apoptosis. Int Rev Cytology 1980; 68: 251-306
133. Dingemans KP, Pels E, Den-Otter W. Destruction of murine lymphoma cells by allogeneic immune peritoneal macrophages in vitro: an ultrastructure study. J Nat Cancer Inst 1981; 66: 67-79
134. van-de-Loosdrecht AA, Ossenkoppele GJ, Beelen RH, Broekhoven MG Drager AM, Langenhuijsen MM. Apoptosis in tumor necrosis factor-alpha-dependent, monocyte-mediated leukemic cell death: a functional, morphologic, and flow-cytometric analysis. Experimental Hematology 1993; 21: 1628-39
135. Cui S, Reichner JS, Mateo RB, Albina JE. Activated murine macrophages induce apoptosis in tumor cells through nitric oxide-dependent or -independent mechanisms. Cancer Research 1994; 54: 2462-7
136. Onozaki K, Matsushima K, Aggarwal BB, Oppenheim JJ. Human interleukin 1 is a cytocidal factor for several tumor cell lines. Journal of Immunology 1985; 135: 3962-8
137. Fratelli M, Gagliardini V, Galli G, Gnocchi P, Ghiara P, Ghezzi P. Autocrine interleukin- 1 beta regulates both proliferation and apoptosis in EL4-6.1 thymoma cells. Blood 1995; 85: 3532-7
138. Robaye B, Mosselmans R, Fiers W, Dumont JE, Galand P. Tumor necrosis factor induces apoptosis (programmed cell death) in normal endothelial cells in vitro. Am J Fathol 1991; 138: 447-53
139. Leist M, Gantner F, Jilg S, Wendel A. Activation of the 55 kDa TNF receptor is necessary and sufficient for TNF-induced liver failure, hepatocyte apoptosis, and nitrite release. Journal of Immunology 1995; 154: 1307-16
140. Tartaglia LA, Ayres TM, Wong GH, Goeddel DV. A novel domain within the 55 kd TNF receptor signals cell death. Cell 1993; 74: 845-53
141. Donato NJ, Perez M. Tumor necrosis factor-induced apoptosis stimulates p53 accumulation and p21WAF1 proteolysis in ME-180 cells. Journal of Biological Chemistry 1998; 273: 5067-72
142. Grel M, Douni E, Wajant H, Lohden M, Clauss M, Maxeiner B, Georgopoulos S, Lesslauer W, Kollias G, Pfizenmaier K, et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 1995; 83: 793-802
143. Web DS, Mostowski HS, Gerrard TL. Cytokine-induced enhancement of ICAM-1 expression results in increased vulnerability of tumor cells to monocyte-mediated lysis. J Immunol 1991; 146: 3682-6
144. Jonjic N, Alberti S, Bernasconi S, Peri G, Jilek P, Anichini A, Parmiani G, Mantovani A. Heterogeneous susceptibility of human melanoma clones to monocyte cytotoxicity: role of ICAM-1 defined by antibody blocking and gene transfer. Eur J Immunol 1992; 22,: 2255-60
145. Hansson M, Asea A, Ersson U, Hermodsson S, Hellstrand K. Induction of apoptosis in NK cells by monocyte-derived reactive oxygen metabolites. J Immunol 1996; 156: 42-7
146. Nathan C. Natural resistance and nitric oxide. Cell 1995; 82: 873-6
147. Denis M. Human monocytes/macrophages: NO or no NO?J Leukoc Biol 1994; 55: 682-4
148. Keller R, Geiges M, Keist R. L-arginine-dependent reactive nitrogen intermediates as mediators of tumor cell killing by activated macrophages. Cancer Research 1990; 50: 1421-5
149. Geng YJ, Hellstrand K, Wennmalm A, Hansson GK. Apoptotic death of human leukemic cells induced by vascular cells expressing nitric oxide synthase in response to gamma-interferon and tumor necrosis factor-alpha. Cancer Research 1996; 56: 866-74
150. Sveinbjornsson B, Olsen R, Seternes OM, Seljelid R. Macrophage cytotoxicity against murine meth A sarcoma involves nitric oxide-mediated apoptosis. Biochem Biophys Res Commun 1996; 223: 643-9
151. Messmer UK, Ankarcrona M, Nicotera P, Brune B. p53 expression in nitric oxide-induced apoptosis. FEBS Letters 1994; 355: 23-6
152. Alleva A, Burger CJ, Elgert KD. Increased sensitivity of tumor-bearing host macrophages to interleukin-10: a counter-balancing action to macrophage-mediated suppression. Oncology Research 1994; 6: 219-28
153. Young MR, Wright MA, Matthews JP, Malik I, Prechel M. Suppression of T cell proliferation by tumor-induced granulocyte-macrophage progenitor cells producing transforming growth factor-beta and nitric oxide. J Immunol 1996; 156: 1916-22
154. Cianciolo GJ. Antiinflammatory effects of neoplasms. Research in Immunology 1993; 144, 268-71; discussion 294-8
155. Zembala M, Siedlar M, Marcinkiewicz J, Pryjma J. Human monocytes are stimulated for nitric oxide release in vitro by some tumor cells but not by cytokines and lipopolysaccharide. Eur J Immunol 1994; 24: 435-9
156. Hoffman RA, Langrehr JM, Billiar TR, Curran RD, Simmons RL. Alloantigen-induced activation of rat splenocytes is regulated by the oxidative metabolism of L-arginine. J Immunol 1990; 145: 2220-6
157. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacological Reviews 1991; 43: 109-42
158. MacMicking J, Xie QW, Nathan C. Nitric oxide and macrophage function. Ann Rev Immunol 1997; 15: 323-50
159. Janicke, R, Mannel DN. Distinct tumor cell membrane constituents activate human monocytes for tumor necrosis factor synthesis. J Immunol 1990; 144: 1144-50
160. Hershkoviz R, Cahalon L, Gilat D, Miron S, Miller A, Lider O. Physically damaged extracellular matrix induces TNF-alpha secretion by interacting resting CD4+ T cells and macrophages. Scand J Immunol 1993; 37: 111-5
161. Fidler IJ, Schroit AJ. Recognition and destruction of neoplastic cells by activated macrophages: discrimination of altered self. Biochim Biophys Acta 1988; 948: 151-73
162. Debets JM, Van-de-Winkel JG, Ceuppens JL, Dieteren IE, Buurman WA. Cross-linking of both Fc gamma RI and Fc gamma RII induces secretion of tumor necrosis factor by human monocytes, requiring high affinity Fc-Fc gamma R interactions. Functional activation of Fc gamma RII by treatment with proteases or neuraminidase. Journal of Immunology 1990; 144: 1304-10
163. Wallace PK, Howell AL, Fanger MW. Role of Fc gamma receptors in cancer and infectious disease. J Leukoc Biol 1994: 55; 816-26.
164. Adams DO, Hamilton TA. The cell biology of macrophage activation.. Annual Review of Immunology 1984; 2: 283-318
165. Klostergaard J. Macrophage tumoricidal mechanisms. Research in Immunology 1993; 144: 274-6
166. Kloke O, Niederle N. Development and mechanisms of interferon resistance. Cancer Treatment Reviews 1990; 17 Suppl A: 81-8
167. Duffie GP, Young MR. Tumoricidal activity of alveolar and peritoneal macrophages of C57BL/6 mice bearing metastatic or nonmetastatic variants of Lewis lung carcinoma. J Leukoc Biol 1991; 49: 8-14
168. Vassalli P. The pathophysiology of tumor necrosis factors. Annual Review of Immunology 1992; 10: 411-52
169. Ding A, Sanchez E, Nathan CF. Taxol shares the ability of bacterial lipopolysaccharide to induce tyrosine phosphorylation of microtubule-associated protein kinase. J Immunol 1993; 151: 5596-602.
170. Micallef MJ, Ohtsuki T, Kohno K, Tanabe F, Ushio S, Namba M, Tanimoto T, Torigoe K, Fujii M, Ikeda M, Fukuda S, Kurimoto M. Interferon-gamma-inducing factor enhances T helper 1 cytokine production by stimulated human T cells: synergism with interleukin-12 for interferon-gamma production. Eur J Immunol 1996; 26: 1647-51
171. Brunda MJ. Interleukin-12. J Leukoc Biol 1994; 55: 280-8
172. Romagnani S. Induction of TH1 and TH2 responses: a key role for the "natural" immune response? Immunol Today 1992; 13: 379-81.
173. Brunda MJ, Luistro L, Rumennik L, Wright RB, Wigginton JM, Wiltrout RH, Hendrzak JA, Palleroni AV. Interleukin-12: murine models of a potent antitumor agent. Annals of the New York Academy of Sciences 1996; 795: 266-74
174. Trinchieri G, Scott P. The role of interleukin 12 in the immune response, disease and therapy. Immunol Today 1994; 15: 460-3. [Comment in: Immunol Today 1995; 16: 500-1]
175. Handel-Fernande ME, Cheng X, Herbert LM, Lopez DM. Down-regulation of IL-12, not a shift from a T helper-1 to a T helper-2 phenotype, is responsible for impaired IFN-gamma production in mammary tumor-bearing mice. J Immunol 1997; 158: 280-6
176. Evans R. Macrophage requirement for growth of a murine fibrosarcoma. British Journal of Cancer 1978; 37: 1086-9
177. Walker TM, Burger CJ, Elgert KD. Tumor growth alters T cell and macrophage production of and responsiveness to granulocyte-macrophage colony-stimulating factor: partial dysregulation through interleukin-10. Cellular Immunology 1994; 154: 342-57
178. Rothe H, Hartmann B, Geerlings P, Kolb H. Interleukin-12 gene-expression of macrophages is regulaged by nitric oxide. Biochem Biophys Res Commun 1996; 224: 159-63
179. Vodovotz Y, Bogdan C. Control of nitric oxide synthase expression by transforming growht factor-beta: implications for homeostasis. Progress in Growth Factor Research 1994; 5: 341-51
180. Gardner TE, Naama H, Daly JM. Peritoneal and splenic macrophage functions in the tumor-bearing host. Journal of Surgical Research 1995; 59: 305-10
181. Nicola NA. Hemopoietic cell growth factors and their receptors. Annual Review of Biochemistry 1989; 58: 45-77
182. Kato T, Inaba K, Ogawa Y, Inaba M, Kakihara K, Shimizu S, Ikehara S, Sudo T, Muramatsu S. Granulocytemacrophage colony-stimulating factor enhances macrophage accessory function in con A-stimulated T-cell proliferation. Cellular Immunology 1990; 130: 490-500
183. Fischer HG, Frosch S, Reske-Kunz AB. Granulocytemacrophage colony-stimulating factor activates macrophages derived from bone marrow cultures to synthesis of MHC class II molecules and to augmented antigen presentation function. J Immunol 1988; 141: 3882-8.
184. Walker TM, Burger CJ, Elgert KD. Tumor growth alters macrophage responsiveness to macrophage colony-stimulating factor during reactivity against allogeneic and syngeneic MHC class II molecules. Immunol Invest 1993; 22: 463-76
185. Sher A, Fiorentino D, Caspar P, Pearce E, Mosmann T. Production of IL-10 by CD4+ T lymphocytes correlates with down-regulation of Th1 cytokine synthesis in helminth infection. J Immunol 1991; 147: 2713-6
186. Bogdan C, Vodovotz Y, Nathan C. Macrophage deactivation by interleukin 10. J Exp Med 1991; 174: 1549-55.
187. Eisenstein TK. Suppressor macrophages. Immunology Series 1994; 60: 203-24
188. Parhar RS, Lala PK. Prostaglandin E2-mediated inactivation of various killer lineage cells by tumor-bearing host macrophages. J Leukoc Biol 1988; 44: 474-84
189. Braun DP, Ahn MC, Harris JE, Chu E, Casey L, Wilbanks G, Siziopikou KP. Sensitivity of tumoricidal function in macrophages from different anatomical sites of cancer patients to modulation of arachidonic acid metabolism. Cancer Research 1993; 53: 3362-8
190. Yurochko AD, Burger CJ, Elgert KD. Tumor modulation of autoreactivity: decreased macrophage and autoreactive T cell interactions. Cellular Immunology 1990: 127: 105-19
191. Unanue ER, Allen PM. The basis for the immunoregulatory role of macrophages and other accessory cells. Science 1987; 236: 551-7
192. Watson GA, Lopez DM. Aberrant antigen presentation by macrophages from tumor-bearing mice is involved in the down-regulation of their T cell responses. J Immunol 1995; 155: 3124-34.
193. Sakata T, Iwagami S, Tsuruta Y, Suzuki S, Suzuki R. Study of natural lipocortin I. A potent mediator for macrophage-mediated immunosuppression in tumor-bearing mice. J Immunol 1993; 151: 4964-72
194. Tomioka H, Saito H. Characterization of immunosuppressive functions of murine peritoneal macrophages induced with various agents. J Leukoc Biol 1992; 51: 24-31
195. Alleva DG, Walker TM, Elgert KD. Induction of macrophage suppressor activity by fibrosarcoma-derived transforming growth factor-beta 1: contrasting effects on resting and activated macrophages. J Leukoc Biol 1995; 57: 919-28
196. Lejeune P, Lagadec P, Onier N, Pinard D, Ohshima H, Jeannin JF. Nitric oxide involvement in tumor-induced immunosuppression. J Immunol 1994; 152: 5077-83
197. Kono K, Salazar-Onfray F, Petersson M, Hansson J, Masucci G, Wasserman K, Nakazawa T, Anderson P, Kiessling R. Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell-and natural killer cell-mediated cytotoxicity. Eur J Immunol 1996; 26: 1308-13
198. de Visser KE, Kast WM. Effects of TGF-beta on the immune system: implications for cancer immunotherapy. Leukemia 1999; 13: 1188-99
199. Sieling PA, Abrams JS, Yamamura M, Salgame P, Bloom BR, Rea TH, Modlin RL. Immunosuppressive roles for IL-10 and IL-4 in human infection. In vitro modulation of T cell responses in leprosy. J Immunol 1993; 150: 5501-10
200. Chouaib S, sselin-Paturel C, Mami-Chouaib F, Caignard A, Blay J. The host-tumor immune conflict: from immunosuppression to resistance and destruction. Immunol Today 1997; 18: 493-7
201. McCartney-Francis NL, Wahl SM. Transforming growth factor beta: a matter of life and death. J Leukoc Biol 1994; 55: 401-9
202. Powrie F, Menon S, Coffman RL. Interleukin-4 and interleukin-10 synergize to inhibit cell-mediated immunity in vivo. Eur J Immunol 1993; 23: 3043-9
203. Niiro H, Otsuka T, S SK, Nemoto Y, Abe M, Hara N, Nakano T, Ogo T, Niho Y. IL- 10 inhibits prostaglandin E2 production by lipopolysaccharide-stimulated monocytes. Internat Immunol 1994; 6, 661-4
204. Merendino RA, Gangemi S, Misefari A, Arena A, Capozza AB, Chillemi S, D'Ambrosio FP. Interleukin- 12 and interleukin-10 production by mononuclear phagocytic cells from breast cancer patients. Immunology Letters 1999; 68: 355-8
205. Bellone G, Turletti A, Artusio E, Mareschi K, Carbone A, Tibaudi D, Robecchi A, Emanuelli G, Rodeck U. Tumor-associated transforming growth factor-beta and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients. Am J Pathol 1999; 155: 537-47